TIVC
Tivic Health Systems Inc
$
3.090
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.1445
Open
3.120
VWAP
3.08
Vol
47.02K
Mkt Cap
3.35M
Low
3.050
Amount
144.73K
EV/EBITDA(TTM)
--
Total Shares
6.18M
EV
2.16M
EV/OCF(TTM)
--
P/S(TTM)
3.85
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q2
1.13M
+601.86%
-102.000
+1357.14%
Estimates Revision
Stock Price
Go Down
-26.43%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Tivic Health Systems Inc (TIVC.O) is 0.00, compared to its 5-year average forward P/E of -0.62. For a more detailed relative valuation and DCF analysis to assess Tivic Health Systems Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.62
Current PE
0.00
Overvalued PE
0.23
Undervalued PE
-1.46
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.27
Current EV/EBITDA
-0.33
Overvalued EV/EBITDA
0.31
Undervalued EV/EBITDA
-0.85
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.22
Current PS
0.41
Overvalued PS
5.18
Undervalued PS
-0.73
Financials
Annual
Quarterly
FY2025Q2
YoY :
-38.57%
86.00K
Total Revenue
FY2025Q2
YoY :
+60.36%
-1.93M
Operating Profit
FY2025Q2
YoY :
+52.53%
-1.93M
Net Income after Tax
FY2025Q2
YoY :
-59.22%
-2.19
EPS - Diluted
FY2025Q2
YoY :
+43.51%
-1.85M
Free Cash Flow
FY2025Q2
YoY :
+193.00%
62.79
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
YoY :
+148.30%
-2.25K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TIVC News & Events
Events Timeline
2025-08-20 (ET)
2025-08-20
08:38:27
Tivic Health Secures Two Investigational New Drug Applications from Statera
2025-07-08 (ET)
2025-07-08
09:15:14
Tivic appoints Lisa Wolf permanent CFO, Chief Scientific Officer to step down
2025-07-08
09:13:31
Tivic shareholders approve key proposals for strategic transformation
Sign Up For More Events
Sign Up For More Events
News
9.0
08-20NewsfilterTivic Secures Two Investigational New Drug Applications for Entolimod™ Targeting Acute Radiation Syndrome (ARS) and Advanced Cancers
3.5
08-15NewsfilterTivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
2.0
08-15NASDAQ.COMStocks Moving Premarket: PMNT, KULR, ENLV, ORGN, And Other Gainers & Losers
Sign Up For More News
People Also Watch
PCSA
Processa Pharmaceuticals Inc
0.189
USD
-10.87%
ASST
Asset Entities Inc
6.150
USD
-8.07%
ENTO
Entero Therapeutics Inc
2.275
USD
+5.81%
DRMA
Dermata Therapeutics Inc
5.740
USD
+7.29%
NVVE
Nuvve Holding Corp
0.385
USD
-10.67%
SYTA
Siyata Mobile Inc
3.060
USD
+3.38%
AUUD
Auddia Inc
2.250
USD
-3.43%
PRFX
PainReform Ltd
1.450
USD
-1.36%
VERO
Venus Concept Inc
2.210
USD
-4.12%
FAQ
What is Tivic Health Systems Inc (TIVC) stock price today?
The current price of TIVC is 3.09 USD — it has increased 0 % in the last trading day.
What is Tivic Health Systems Inc (TIVC)'s business?
What is the price predicton of TIVC Stock?
What is Tivic Health Systems Inc (TIVC)'s revenue for the last quarter?
What is Tivic Health Systems Inc (TIVC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Tivic Health Systems Inc (TIVC)'s fundamentals?
How many employees does Tivic Health Systems Inc (TIVC). have?